Fig. 2.
Unprimed ex vivo proliferation assays of fresh T cells from vaccinated patients.
The assay was conducted as described in “Materials and Methods.” (A) Patient 7 after 5 vaccinations. (B) Patient 7 after 8 vaccinations. (C) Patient 8 after 3 vaccinations. (D) Patient 11 after 5 vaccinations. The stimulus is shown along the x-axis. T+ø, T cells plus APC without peptide; CML bulk is 5 peptides in the vaccine (see Figure 1); control bulk is control peptides (see “Materials and Methods”); b3a2 20 or b3a2 50 is 20μg or 50μg of the long b3a2 peptide (Figure 1); ras 20 or ras 50 is 20μg or 50μg of the control ras peptide (see “Materials and methods”). Standard deviations are shown.